[A21-60] Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V
Last updated 04.11.2021
Project no.:
A21-60
Commission:
Commission awarded on 12.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with multiple myeloma who have received at least one prior therapy
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-61 | Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide und dexamethasone) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-123 | Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib and dexamethasone) - Addendum to Commission A21-60 | Commission completed |
Federal Joint Committee (G-BA)
2021-11-04 A G-BA decision was published.
G-BA documents on this decision